FY March 2026 Q3 Financial Summary [Japanese GAAP] (Consolidated)

Overview of Financial Results

For the nine months ended March 2026, net sales amounted to ¥522,415 million (6.1% YoY increase), operating income was ¥14,450 million (4.4% YoY decrease), ordinary income was ¥15,462 million (6.5% YoY decrease), and net income attributable to owners of parent for the quarter was ¥9,381 million (10.8% YoY decrease). Although the medical industry continues to face price inflation and labor shortages, signs of future improvement are emerging with the new Takashi administration’s supplementary budget and the announcement of medical fee revisions.

Segment Performance

Total Pack Produce business recorded net sales of ¥89,898 million (3.0% YoY increase) but profits declined. Medical Supply business posted net sales of ¥378,475 million (7.5% YoY increase) with profits increasing. Life Care business reported net sales of ¥28,158 million (1.9% YoY increase) with profits decreasing. Dispensing Pharmacy business achieved net sales of ¥25,883 million (2.8% YoY increase) with profits increasing. Operational efficiency has improved through small-scale M&As and restructuring.

Financial Position and Share-related Information

Total assets were ¥388,940 million (increase from previous fiscal year-end), net assets were ¥149,253 million (decrease from previous fiscal year-end), and equity ratio was 38.1% (decreased 1.0 points). The number of shares outstanding at period-end was 94,350,134 shares, with treasury shares at 2,331,200 shares. The number of shares decreased due to treasury stock acquisitions.

Earnings Guidance

Full-year earnings forecast for FY March 2026 remains unchanged: net sales of ¥700,000 million (3.2% YoY increase), operating income of ¥26,000 million (4.9% YoY increase), ordinary income of ¥26,500 million (1.8% YoY increase), net income attributable to owners of parent of ¥15,500 million (2.5% YoY increase), and earnings per share of ¥166.85.